What's new in bacterial vaginosis and trichomoniasis?
The use of biochemical profiles and new molecular microbiologic methodologies is transforming our understanding of BV. Most important is the recognition of different subgroups of women who have BV who are at variable risk of certain obstetric and gynecologic complications. New diagnostic tests may soon be available that will allow women to test self-obtained specimens. Treatment of BV has lagged, although innovative methods appear to be helpful in managing recurrent diseases.
Sobel
Jack D
JD
Harper University Hospital, Division of Infectious Diseases, 3990 John R-5 Hudson, Detroit, MI 48201, USA. jsobel@med.wayne.edu
D000890:Anti-Infective Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000209:etiology / Q000503:physiopathology; D015995:Prevalence; D014245:Trichomonas Infections / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D014481:United States / Q000453:epidemiology; D016585:Vaginosis, Bacterial / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology
D000890:Anti-Infective Agents